Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. - Goncalves MB; Mant T; Täubel J; Clarke E; Hassanin H; Bendel D; Fok H; Posner J; Holmes J; Mander AP; Corcoran JPT (British journal of clinical pharmacology, 2023)